177Lu-octreotate Can Improve QOL in Patients With Gastroenteropancreatic Tumours: Presented at ENETS
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




177Lu-octreotate Can Improve QOL in Patients With Gastroenteropancreatic Tumours: Presented at ENETS

By Karen Dente

BERLIN -- March 14, 2010 -- Quality of life (QOL) can be improved in patients with inoperable bronchial carcinoids or metastasised gastroenteropancreatic neuroendocrine tumours with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate) treatment, according to recent findings presented here at the 7th European Neuroendocrine Tumor Society Conference (ENETS).

A total of 265 patients were treated with 177Lu-octreotate and asked to complete the QOL questionnaire C30 version 3.0 of the European Organization for the Research and Treatment of Cancer.

“Self-reported QOL is considered an important outcome for the effect of treatment nowadays, regardless of treatment outcome,” wrote researchers from Erasmus University Rotterdam, Rotterdam, the Netherlands.

Patient-based differences of at least 10 points in scores before and after treatment were regarded as a significant clinical improvement in QOL and symptoms (analysis of variance, P <= .05).

Other signs of clinical improvement were a 3 kg weight gain, an increase of at least 10 points on the Karnofsky Performance Scale (KPS), and a decrease of >=50% in serum chromogranin A.

“Overall, a significant improvement in QOL and symptoms of insomnia, diarrhoea, and appetite loss was seen independently of the clinical outcome,” the authors reported.

In the subgroup of patients with remission, KPS and fatigue improved significantly as well. In patients who had symptoms before therapy, nausea and vomiting improved by 70%, and diarrhoea improved by 67%.

The researchers concluded that 177Lu-octreotate therapy not only affects tumour growth and overall survival but also improves symptoms and QOL after therapy.

[Presentation title: Quality of Life in 265 Patients With Gastroenteropancreatic Tumors or Bronchial Carcioids Treated With [177Lu-DOTA0, Tyr3]octreotate. Abstract C46]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities